# An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®

> **NCT01046903** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 503 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Fragmin® (Dalteparin Sodium)

## Key facts

- **NCT ID:** NCT01046903
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2012-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046903, "An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01046903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*